Skip to content

FOAM-study, Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins

FOAM-study Cost Minimization Study Comparing Surgery Versus Duplex Guided Foam Sclerotherapy of Varicose Veins: a Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01103258
Enrollment
460
Registered
2010-04-14
Start date
2006-02-28
Completion date
2010-01-31
Last updated
2010-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Varicose Vein Disease

Keywords

Incompetence of the great saphenous vein.

Brief summary

Varicose vein disease is a common health problem, which causes much discomfort to patients. Nowadays treatment modalities for greater saphenous veins include surgery and duplex guided foam sclerotherapy. These are two equally accepted and applied treatments for the same patient population. Choice of treatment often depends on the referral preference of the General Practitioner. Until now data are missing which treatment is more cost effective. The current proposal aims at comparing the effects, costs and patient preferences between duplex guided foam sclerotherapy and surgery in the treatment of greater varicose veins.

Interventions

PROCEDUREhigh ligation and stripping (surgery)

surgery consisting of high ligation in combination with long saphenous stripping

PROCEDUREFOAM

duplex guided foam sclerotherapy

Sponsors

ZonMw: The Netherlands Organisation for Health Research and Development
CollaboratorOTHER
Maastricht University Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* incompetence of great saphenous vein for minimal 20 cm * life expectancy at least 3 years * open and competent deep venous system * willing to undergo both treatments

Exclusion criteria

* active ulcer * signs of deep venous thrombosis with duplex * incompetence of the deep venous system

Design outcomes

Primary

MeasureTime frame
cumulative probability of recurrent varicose vein within 24 months after treatment24 months

Secondary

MeasureTime frameDescription
quality of life (as measured by EuroQol-5D)24 months
patient preferences (as measured by conjoint analysis)24 months
direct Health care costs24 monthsmaterials, operation costs, personnel costs

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026